CA 19-9 as a serum marker in urothelial carcinoma

被引:17
作者
Pall, Mahander [1 ]
Iqbal, Javid [1 ]
Singh, Shrawan Kumar [2 ]
Rana, Satya Vati [3 ]
机构
[1] PGIMER, Dept Gen Surg, Sect 12, Chandigarh 160012, India
[2] PGIMER, Dept Urol, Chandigarh, India
[3] PGIMER, Dept Gastroenterol, Chandigarh, India
关键词
CA19-9; screening; tumor marker; urothelial carcinoma;
D O I
10.4103/0974-7796.95555
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: CA 19-9 is a carbohydrate antigen related to Lewis A blood group antigen. It is well-known marker for pancreatic carcinoma and is being investigated for other malignancies including carcinoma bladder. We evaluated the role of serum CA 19-9 as a tumor marker and correlated its level with tumor stage and grade. Materials and Methods: Seventy-five patients with histologically proven urothelial carcinoma were included in this study as case and 25 healthy volunteers as control. Preoperative 5 ml blood sample was collected. Serum level of CA 19-9 was measured using solid-phase enzyme-linked immunosorbent assay kit. The value of CA19-9 was expressed in U/ml and 37 U/ml was taken as cut-off upper value of normal. Results: The range of CA19-9 in patients of urothelial carcinoma was 2 to 122 U/ml with a mean of 26.33 +/- 29.28, while in control, it was 8.48 +/- 5.01 U/ml ( P<0.001). The sensitivity of CA19-9 was 29%. Serum CA19-9 was significantly elevated in invasive disease in comparison with superficial disease (47.17 +/- 34.43 vs 16.53 +/- 20.13) (P<0.001). Significantly high proportion of patients with invasive disease had value >= 37 U/ml (14/24 [58.3%] vs 8/51 [15.7%]) with P value <0.001. High proportion of high-grade tumor had raised value, 14/34 (41.25%); all patients with metastatic disease had value more than 37 U/ml. Conclusions: Serum CA19-9 is a marker of aggressiveness of urothelial carcinoma and is almost invariably raised in patients with metastatic disease. Thus, it may be used as a prognostic marker but not as a screening tool due to its low sensitivity.
引用
收藏
页码:98 / 101
页数:4
相关论文
共 25 条
[1]   Cystectomy for bladder cancer: A contemporary series [J].
Dalbagni, G ;
Genega, E ;
Hashibe, M ;
Zhang, ZF ;
Russo, P ;
Herr, H ;
Reuter, V .
JOURNAL OF UROLOGY, 2001, 165 (04) :1111-1116
[2]  
DELVILLANO BC, 1983, CLIN CHEM, V29, P549
[3]   The World Health Organization International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder [J].
Epstein, JI ;
Amin, MB ;
Reuter, VR ;
Mostofi, FK .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1998, 22 (12) :1435-1448
[4]   URINARY FIBRIN FIBRINOGEN DEGRADATION PRODUCTS IN TRANSITIONAL CELL-CARCINOMA OF THE BLADDER [J].
EWING, R ;
TATE, GM ;
HETHERINGTON, JW .
BRITISH JOURNAL OF UROLOGY, 1987, 59 (01) :53-58
[5]   Cancer statistics, 2000 [J].
Greenlee, RT ;
Murray, T ;
Bolden, S ;
Wingo, PA .
CA-A CANCER JOURNAL FOR CLINICIANS, 2000, 50 (01) :7-33
[6]  
Grossman H B, 1998, Semin Urol Oncol, V16, P17
[7]  
Hegele A, 2010, ANTICANCER RES, V30, P5195
[8]  
Hirano K, 1987, JNCI-J NATL CANCER I
[9]   NEW CARBOHYDRATE TUMOR-MARKERS [J].
ITZKOWITZ, SH ;
KIM, YS .
GASTROENTEROLOGY, 1986, 90 (02) :491-494
[10]  
ITZKOWITZ SH, 1988, CANCER RES, V48, P3834